We are live on ! Find out more
ARLZ

Aralez Pharmaceuticals Inc.
ARLZ

Delisted

ARLZ was delisted on the 20th of August, 2018.

Back to rankings

63 hedge funds and large institutions have $17.1M invested in Aralez Pharmaceuticals Inc. in 2017 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 16 increasing their positions, 17 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

57% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 7

7% more funds holding

Funds holding: 59 → 63 (+4)

6% less repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 17

42% less capital invested

Capital invested by funds: $29.6M → $17.1M (-$12.5M)

64% less call options, than puts

Call options by funds: $63K | Put options by funds: $175K

Holders
63
Holders Change
+4
Holders Change %
+6.78%
% of All Funds
1.43%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
16
Reduced
17
Closed
7
Calls
$63K
Puts
$175K
Net Calls
-$112K
Net Calls Change
-$178K

Top Buyers

Rank Fund Capital Flow
1
Wells Fargo
Wells Fargo
California
+$679K
2
Goldman Sachs
Goldman Sachs
New York
+$264K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$156K
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$136K
5
Millennium Management
Millennium Management
New York
+$108K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$2.28M
2
PCM
PAR Capital Management
Massachusetts
-$751K
3
CIM
Contrarius Investment Management
Jersey
-$495K
4
Deutsche Bank
Deutsche Bank
Germany
-$451K
5
GCP
GSA Capital Partners
United Kingdom
-$123K
Name Holding Trade Value Shares
Change 		Change in
Stake
Renaissance Technologies
26
Renaissance Technologies
New York
$63K +$72.4K +44,100 New
VF
27
Virtu Financial
New York
$61K +$22.3K +13,572 +46%
JMPWA
28
JP Morgan Private Wealth Advisors
California
$57K -$32.8K -20,000 -33%
Barclays
29
Barclays
United Kingdom
$54K +$62.9K +38,342 New
Acadian Asset Management
30
Acadian Asset Management
Massachusetts
$39K +$44.9K +27,383 New
Citadel Advisors
31
Citadel Advisors
Florida
$34K +$39.3K +23,961 New
NL
32
NWAM LLC
Washington
$28K -$11.5K -7,000 -26%
SRC
33
Shufro Rose & Co
New York
$26K – – –
SC
34
Scotia Capital
Ontario, Canada
$26K +$5.25K +3,200 +21%
JG
35
Jefferies Group
New York
$25K +$28.4K +17,300 New
TSS
36
Two Sigma Securities
New York
$24K +$27.2K +16,550 New
Squarepoint
37
Squarepoint
New York
$24K +$27.2K +16,600 New
BAM
38
Berkshire Asset Management
Pennsylvania
$21K +$24.6K +15,000 New
Group One Trading
39
Group One Trading
Illinois
$18K +$18.1K +11,000 +826%
JP Morgan Chase
40
JP Morgan Chase
New York
$14K -$2.02K -1,234 -12%
FAAS
41
First Allied Advisory Services
California
$14K – – –
GT
42
Glenmede Trust
Pennsylvania
$11K -$3.12K -1,900 -19%
AG
43
Advisor Group
Arizona
$9K -$3.68K -2,240 -27%
LTFS
44
Ladenburg Thalmann Financial Services
Florida
$8K – – –
Bank of America
45
Bank of America
North Carolina
$7K -$27.5K -16,728 -77%
TRCT
46
Tower Research Capital (TRC)
New York
$7K +$5.77K +3,516 +251%
UBS Group
47
UBS Group
Switzerland
$6K -$18.2K -11,082 -72%
Royal Bank of Canada
48
Royal Bank of Canada
Ontario, Canada
$6K +$2.54K +1,548 +52%
FDCDDQ
49
Federation des caisses Desjardins du Quebec
Quebec, Canada
$5.03K -$596 -363 -9%
CIBC Private Wealth Group
50
CIBC Private Wealth Group
Georgia
$5K +$5.52K +3,362 New
1
2
3

ARLZ Hedge Fund Activity: Q4 2017 in Review

63 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Aralez Pharmaceuticals Inc. (ARLZ) for Q4 2017, worth a combined $17.1M — down 42% from $29.6M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new ARLZ positions and 7 closed out — a net gain of 4 holders — while 16 added to existing stakes and 17 trimmed.

The largest buyer was Wells Fargo, adding an estimated $679K. The largest seller was BlackRock, exiting entirely with an estimated $2.28M sold.

  • 63 institutional investors held Aralez Pharmaceuticals Inc. (ARLZ) as of Q4 2017, up from 59 in Q3 2017.
  • Funds reported $17.1M of Aralez Pharmaceuticals Inc. stock for Q4 2017, down 42% quarter-over-quarter.
  • 11 funds opened new Aralez Pharmaceuticals Inc. positions in Q4 2017 and 7 closed out, a net change of +4 holders.
  • The largest Aralez Pharmaceuticals Inc. buyer in Q4 2017 was Wells Fargo, an estimated $679K added.
  • The largest Aralez Pharmaceuticals Inc. seller in Q4 2017 was BlackRock, an estimated $2.28M sold.

Based on aggregated 13F filings for Q4 2017.